FMS vs. TAK: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at FMS and TAK, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
Both FMS and TAK are American Depositary Receipts (ADRs). This provides U.S. investors with straightforward access to investing in these foreign-listed companies.
| Symbol | FMS | TAK |
|---|---|---|
| Company Name | Fresenius Medical Care AG | Takeda Pharmaceutical Company Limited |
| Country | Germany | Japan |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Health Care Providers & Services | Pharmaceuticals |
| Market Capitalization | 15.74 billion USD | 46.64 billion USD |
| Exchange | NYSE | NYSE |
| Listing Date | September 17, 1996 | January 5, 2010 |
| Security Type | ADR | ADR |
Historical Performance
This chart compares the performance of FMS and TAK by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | FMS | TAK |
|---|---|---|
| 5-Day Price Return | 4.17% | -0.51% |
| 13-Week Price Return | -4.77% | -3.10% |
| 26-Week Price Return | -0.85% | -6.75% |
| 52-Week Price Return | 20.38% | 5.51% |
| Month-to-Date Return | 1.86% | -1.32% |
| Year-to-Date Return | 3.01% | 1.84% |
| 10-Day Avg. Volume | 0.57M | 5.21M |
| 3-Month Avg. Volume | 0.54M | 4.30M |
| 3-Month Volatility | 21.87% | 18.77% |
| Beta | 0.59 | 0.38 |
Profitability
Return on Equity (TTM)
FMS
4.70%
Health Care Providers & Services Industry
- Max
- 24.86%
- Q3
- 15.79%
- Median
- 8.56%
- Q1
- 5.75%
- Min
- -1.64%
FMS’s Return on Equity of 4.70% is in the lower quartile for the Health Care Providers & Services industry. This indicates a less efficient generation of profit from its equity base when compared to its competitors.
TAK
1.95%
Pharmaceuticals Industry
- Max
- 38.59%
- Q3
- 19.84%
- Median
- 11.85%
- Q1
- 5.40%
- Min
- -10.91%
TAK’s Return on Equity of 1.95% is in the lower quartile for the Pharmaceuticals industry. This indicates a less efficient generation of profit from its equity base when compared to its competitors.
Net Profit Margin (TTM)
FMS
3.36%
Health Care Providers & Services Industry
- Max
- 11.56%
- Q3
- 5.45%
- Median
- 2.83%
- Q1
- 1.13%
- Min
- -1.71%
FMS’s Net Profit Margin of 3.36% is aligned with the median group of its peers in the Health Care Providers & Services industry. This indicates its ability to convert revenue into profit is typical for the sector.
TAK
3.06%
Pharmaceuticals Industry
- Max
- 40.67%
- Q3
- 19.07%
- Median
- 12.31%
- Q1
- 4.50%
- Min
- -9.91%
Falling into the lower quartile for the Pharmaceuticals industry, TAK’s Net Profit Margin of 3.06% indicates weaker profitability. This means the company retains a smaller portion of each dollar in sales as profit compared to its competitors.
Operating Profit Margin (TTM)
FMS
7.57%
Health Care Providers & Services Industry
- Max
- 19.08%
- Q3
- 9.66%
- Median
- 4.77%
- Q1
- 2.46%
- Min
- -0.83%
FMS’s Operating Profit Margin of 7.57% is around the midpoint for the Health Care Providers & Services industry, indicating that its efficiency in managing core business operations is typical for the sector.
TAK
8.05%
Pharmaceuticals Industry
- Max
- 45.78%
- Q3
- 23.14%
- Median
- 16.68%
- Q1
- 7.98%
- Min
- -7.13%
TAK’s Operating Profit Margin of 8.05% is around the midpoint for the Pharmaceuticals industry, indicating that its efficiency in managing core business operations is typical for the sector.
Profitability at a Glance
| Symbol | FMS | TAK |
|---|---|---|
| Return on Equity (TTM) | 4.70% | 1.95% |
| Return on Assets (TTM) | 2.02% | 0.95% |
| Net Profit Margin (TTM) | 3.36% | 3.06% |
| Operating Profit Margin (TTM) | 7.57% | 8.05% |
| Gross Profit Margin (TTM) | 24.67% | 64.78% |
Financial Strength
Current Ratio (MRQ)
FMS
1.44
Health Care Providers & Services Industry
- Max
- 2.00
- Q3
- 1.51
- Median
- 1.29
- Q1
- 0.92
- Min
- 0.14
FMS’s Current Ratio of 1.44 aligns with the median group of the Health Care Providers & Services industry, indicating that its short-term liquidity is in line with its sector peers.
TAK
1.16
Pharmaceuticals Industry
- Max
- 4.65
- Q3
- 2.64
- Median
- 1.85
- Q1
- 1.26
- Min
- 0.78
TAK’s Current Ratio of 1.16 falls into the lower quartile for the Pharmaceuticals industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
Debt-to-Equity Ratio (MRQ)
FMS
0.83
Health Care Providers & Services Industry
- Max
- 2.29
- Q3
- 1.24
- Median
- 0.74
- Q1
- 0.50
- Min
- 0.00
FMS’s Debt-to-Equity Ratio of 0.83 is typical for the Health Care Providers & Services industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
TAK
0.66
Pharmaceuticals Industry
- Max
- 1.75
- Q3
- 0.82
- Median
- 0.35
- Q1
- 0.13
- Min
- 0.00
TAK’s Debt-to-Equity Ratio of 0.66 is typical for the Pharmaceuticals industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
Interest Coverage Ratio (TTM)
FMS
5.73
Health Care Providers & Services Industry
- Max
- 14.47
- Q3
- 7.50
- Median
- 4.52
- Q1
- 2.12
- Min
- -4.44
FMS’s Interest Coverage Ratio of 5.73 is positioned comfortably within the norm for the Health Care Providers & Services industry, indicating a standard and healthy capacity to cover its interest payments.
TAK
1.96
Pharmaceuticals Industry
- Max
- 103.95
- Q3
- 43.60
- Median
- 9.83
- Q1
- 2.37
- Min
- -42.71
In the lower quartile for the Pharmaceuticals industry, TAK’s Interest Coverage Ratio of 1.96 indicates a tighter cushion for servicing debt, suggesting less financial flexibility than many of its competitors.
Financial Strength at a Glance
| Symbol | FMS | TAK |
|---|---|---|
| Current Ratio (MRQ) | 1.44 | 1.16 |
| Quick Ratio (MRQ) | 1.08 | 0.59 |
| Debt-to-Equity Ratio (MRQ) | 0.83 | 0.66 |
| Interest Coverage Ratio (TTM) | 5.73 | 1.96 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
FMS
3.20%
Health Care Providers & Services Industry
- Max
- 5.93%
- Q3
- 2.59%
- Median
- 1.35%
- Q1
- 0.00%
- Min
- 0.00%
With a Dividend Yield of 3.20%, FMS offers a more attractive income stream than most of its peers in the Health Care Providers & Services industry, signaling a strong commitment to shareholder returns.
TAK
4.55%
Pharmaceuticals Industry
- Max
- 7.14%
- Q3
- 3.45%
- Median
- 2.17%
- Q1
- 0.33%
- Min
- 0.00%
With a Dividend Yield of 4.55%, TAK offers a more attractive income stream than most of its peers in the Pharmaceuticals industry, signaling a strong commitment to shareholder returns.
Dividend Payout Ratio (TTM)
FMS
187.56%
Health Care Providers & Services Industry
- Max
- 185.33%
- Q3
- 74.82%
- Median
- 36.00%
- Q1
- 0.00%
- Min
- 0.00%
At 187.56%, FMS’s Dividend Payout Ratio is exceptionally high, exceeding the typical range for the Health Care Providers & Services industry. While this provides a significant return to shareholders, it may limit funds for reinvestment and could be difficult to sustain.
TAK
124.94%
Pharmaceuticals Industry
- Max
- 199.58%
- Q3
- 97.17%
- Median
- 53.47%
- Q1
- 22.97%
- Min
- 0.00%
TAK’s Dividend Payout Ratio of 124.94% is in the upper quartile for the Pharmaceuticals industry. This indicates a strong commitment to shareholder returns but also suggests that a smaller portion of earnings is retained for reinvestment compared to many peers.
Dividend at a Glance
| Symbol | FMS | TAK |
|---|---|---|
| Dividend Yield (TTM) | 3.20% | 4.55% |
| Dividend Payout Ratio (TTM) | 187.56% | 124.94% |
Valuation
Price-to-Earnings Ratio (TTM)
FMS
20.14
Health Care Providers & Services Industry
- Max
- 40.02
- Q3
- 29.75
- Median
- 21.09
- Q1
- 14.18
- Min
- 7.05
FMS’s P/E Ratio of 20.14 is within the middle range for the Health Care Providers & Services industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
TAK
49.74
Pharmaceuticals Industry
- Max
- 45.19
- Q3
- 27.91
- Median
- 20.59
- Q1
- 15.08
- Min
- 3.79
At 49.74, TAK’s P/E Ratio is exceptionally high, exceeding the typical maximum for the Pharmaceuticals industry. This suggests the stock may be significantly overvalued compared to its peers and implies high market expectations that could be difficult to meet.
Price-to-Sales Ratio (TTM)
FMS
0.68
Health Care Providers & Services Industry
- Max
- 3.15
- Q3
- 1.87
- Median
- 0.74
- Q1
- 0.27
- Min
- 0.09
FMS’s P/S Ratio of 0.68 aligns with the market consensus for the Health Care Providers & Services industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
TAK
1.52
Pharmaceuticals Industry
- Max
- 8.87
- Q3
- 4.56
- Median
- 2.14
- Q1
- 1.58
- Min
- 0.11
In the lower quartile for the Pharmaceuticals industry, TAK’s P/S Ratio of 1.52 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.
Price-to-Book Ratio (MRQ)
FMS
1.07
Health Care Providers & Services Industry
- Max
- 7.33
- Q3
- 4.45
- Median
- 2.52
- Q1
- 1.15
- Min
- 0.66
FMS’s P/B Ratio of 1.07 is in the lower quartile for the Health Care Providers & Services industry. From a value investing perspective, this is favorable, as it suggests the stock is trading at a discount to its net asset value and may offer a greater margin of safety.
TAK
1.03
Pharmaceuticals Industry
- Max
- 9.78
- Q3
- 4.99
- Median
- 2.48
- Q1
- 1.53
- Min
- 0.59
TAK’s P/B Ratio of 1.03 is in the lower quartile for the Pharmaceuticals industry. From a value investing perspective, this is favorable, as it suggests the stock is trading at a discount to its net asset value and may offer a greater margin of safety.
Valuation at a Glance
| Symbol | FMS | TAK |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 20.14 | 49.74 |
| Price-to-Sales Ratio (TTM) | 0.68 | 1.52 |
| Price-to-Book Ratio (MRQ) | 1.07 | 1.03 |
| Price-to-Free Cash Flow Ratio (TTM) | 6.56 | 8.33 |